Several biomarkers used to guide therapy selection, such as programmed death-ligand 1 (PD-L1) expression, tumor mutation burden (TMB), and microsatellite instability (MSI), often rely on invasive tumor tissue biopsies (Anagnostou et al. 2022). This evidence concerns the gene CD274 and neoplasm.